Nurix strikes $2.3 billion Roche pact for BTK degrader bexobrutideg

Nurix Therapeutics reported on July 9, 2026 that it has entered into a global collaboration with Roche, expecting to receive a $700 million upfront payment within 30 days after the agreement takes effect, with total potential payments of up to $2.3 billion including that upfront amount¹. Development costs will be split 40% Nurix and 60% Roche, U.S. profits and losses will be shared equally, and Nurix is eligible for tiered royalties on sales outside the U.S.¹ The deal covers a broad development plan across several blood cancers and extends into immune-mediated diseases, with planned Phase 2 studies in multiple sclerosis and chronic spontaneous urticaria¹. Closing still depends on standard conditions including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other antitrust reviews¹.

On the clinical side, Nurix presented new and updated data from the ongoing Phase 1a/1b study (NX-5948-301) at EHA showing durable responses and a favorable tolerability profile in relapsed/refractory CLL/SLL patients¹. Updated Phase 1a results showed a median progression-free survival of 22.1 months and an objective response rate of 83%, with activity seen even in patients with BTK resistance mutations, high-risk molecular features, and CNS involvement¹. The Phase 3 confirmatory trial, DAYBreak CLL-306, comparing bexobrutideg to pirtobrutinib is expected to dose its first patient in mid-2026.¹ A healthy-volunteer study of a new tablet formulation continues, with planning underway for Phase 2 trials in CSU and MS.¹

Financially, cash, cash equivalents and marketable securities stood at $443.5 million as of May 31, 2026, down from $592.9 million as of November 30, 2025¹. The company expects to receive the $700 million Roche upfront payment in the third fiscal quarter of 2026¹, and separately noted pro-forma cash of approximately $1.14 billion including that expected payment¹.